Hjem
Jennifer Gjerdes bilde

Jennifer Gjerde

Gjesteforsker
  • E-postjennifer.gjerde@uib.no
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • Vis forfatter(e) (2022). Shotgun proteomics approaches for authentication, biological analyses, and allergen detection in feed and food-grade insect species. Food Control. 1-11.
  • Vis forfatter(e) (2020). Validation and Determination of 25(OH) Vitamin D and 3-Epi25(OH)D3 in Breastmilk and Maternal- and Infant Plasma during Breastfeeding. Nutrients. 18 sider.
  • Vis forfatter(e) (2019). Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer. The Pharmacogenomics Journal. 1-8.
  • Vis forfatter(e) (2019). Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database. Breast Cancer Research and Treatment. 185-195.
  • Vis forfatter(e) (2016). A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen. Breast Cancer Research and Treatment. 97-108.
  • Vis forfatter(e) (2015). The active tamoxifen metabolite endoxifen (4OHNDtam) strongly down-regulates cytokeratin 6 (CK6) in MCF-7 breast cancer cells. PLOS ONE. 19 sider.
  • Vis forfatter(e) (2015). Estrogens correlate with PELP1 expression in ER positive breast cancer. PLOS ONE. 12 sider.
  • Vis forfatter(e) (2014). Phospholipids from herring roe improve plasma lipids and glucose tolerance in healthy, young adults. Lipids in Health and Disease.
  • Vis forfatter(e) (2014). Illness uncertainty in breast cancer patients: Validation of the 5-item short form of the Mishel Uncertainty in Illness Scale. European Journal of Oncology Nursing. 1-7.
  • Vis forfatter(e) (2013). Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment. Breast Cancer Research and Treatment. 243-248.
  • Vis forfatter(e) (2013). Changes in adipose glucocorticoid metabolism before and after bariatric surgery assessed by direct hormone measurements. Obesity. 2495-2503.
  • Vis forfatter(e) (2013). A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Research. 11 sider.
  • Vis forfatter(e) (2012). Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide. Breast Cancer Research and Treatment. 693-700.
  • Vis forfatter(e) (2012). The nuclear receptors NUR77, NURR1 and NOR1 in obesity and during fat loss. International Journal of Obesity. 1195-1202.
  • Vis forfatter(e) (2012). Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer. BMC Cancer. 12 sider.
  • Vis forfatter(e) (2011). Functional polymorphisms in UDP-glucuronosyltransferases and recurrence in tamoxifen-treated breast cancer survivors. Cancer Epidemiology, Biomarkers and Prevention. 1937-1943.
  • Vis forfatter(e) (2011). Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial. The Pharmacogenomics Journal. 100-107.
  • Vis forfatter(e) (2010). Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue. Clinical Cancer Research. 2176-2186.
  • Vis forfatter(e) (2010). Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer. 13 sider.
  • Vis forfatter(e) (2008). Tamoxifen impairs both longitudinal and cortical bone growth in young male rats. Journal of Bone and Mineral Research. 1267-1277.
  • Vis forfatter(e) (2008). Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Annals of Oncology. 56-61.
  • Vis forfatter(e) (2007). Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users. Journal of Clinical Oncology. 4201-4209.
  • Vis forfatter(e) (2007). A study of association between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferae 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady sate tamoxifen treatment. Breast Cancer Research and Treatment. S144-S144.
  • Vis forfatter(e) (2006). Pretreatment with tamoxifen does not change acute epirubicin cardiotoxicity in rats. Basic & Clinical Pharmacology & Toxicology. 231-234.
  • Vis forfatter(e) (2005). Induction of hepatic drug-metabolising enzymes and tamoxifen metabolite profile in relation to administration route during low-dose treatment in nude rats. Journal of Steroid Biochemistry and Molecular Biology. 489-498.
  • Vis forfatter(e) (2005). Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry. Journal of Chromatography A. 6-14.
  • Vis forfatter(e) (2004). Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in randomized preoperative trial. Clinical Cancer Research. 2336-2343.
  • Vis forfatter(e) (2003). Tamoxifen administration and metabolism in nude mice and nude rats. Journal of Steroid Biochemistry and Molecular Biology. 361-367.
Vitenskapelig foredrag
  • Vis forfatter(e) (2010). Estrogen Receptor degradation.
  • Vis forfatter(e) (2005). Distribution of tamoxifen in serum and breast cancer tissue and its effects on sex hormone-binding globulin (SHBG).
Leserinnlegg
  • Vis forfatter(e) (2013). Breaking away: High fracture rates may merit a new trial of adjuvant endocrine therapy in Scandinavian breast cancer patients. Acta Oncologica. 861-U216.
Mastergradsoppgave
  • Vis forfatter(e) (2010). CYP2C19 single nucleotide polymorphisms And their effects on the metabolism of Tamoxifen in breast cancer patients.
Doktorgradsavhandling
  • Vis forfatter(e) (2008). Tamoxifen treatment of breast cancer: Pharmacogenetics and therapeutic drug monitoring.
Vitenskapelig Kapittel/Artikkel/Konferanseartikkel
  • Vis forfatter(e) (2018). Effect of Whey and Herring Roe Protein administered as a supplement to young healthy adults – A pilot study.
  • Vis forfatter(e) (2012). Tamoxifen metabolism and biological activity. 22 sider.
  • Vis forfatter(e) (2011). Steroid Receptor Coactivators and Their Expression, Regulation and Functional Role in Endocrine Responsive and Resistant Breast Cancer. 18 sider.
  • Vis forfatter(e) (2011). Steroid Receptor Coactivators and Endocrine Treatment in Breast Cancer. 32 sider.
Sammendrag/abstract
  • Vis forfatter(e) (2013). Associations between tamoxifen and age during steady state tamoxifen treatment of postmenopausal women with breast cancer. Experimental and clinical endocrinology & diabetes. 1 sider.
  • Vis forfatter(e) (2010). Effects of CYP2C19 genotype on tamoxifen and estrogen metabolism. European Journal of Cancer. 60-60.
  • Vis forfatter(e) (2008). A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment. 592-592.
  • Vis forfatter(e) (2007). Effect of CYP2D6 and SULT1A1 genotypes on the serum concentration of 4-hydroxytamoxifen and 4-hydroxy-N-demethyltamoxifen during steady state treatment of breast cancer patients. Breast. S15-S15.
  • Vis forfatter(e) (2007). A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment.
  • Vis forfatter(e) (2005). Relationship between CYP2D6 and SULT1A1 genotypes and serum concentrations of tamoxifen and its metabolites during steady state treatment in breast cancer patients. Breast Cancer Research and Treatment. S236-S237.
Poster
  • Vis forfatter(e) (2018). A prospective, longitudinal, breast cancer biobank (PBCB) in western Norway.
  • Vis forfatter(e) (2011). The nuclear receptors NURR77, NURR1 and NOR1 in obesity and during fat loss.
  • Vis forfatter(e) (2010). The influence of tamoxifen treatment on the expression levels of liver receptor homolog (LHR-1).
  • Vis forfatter(e) (2010). Expression of Steroid Receptor Coactivators and HER-2/neu in normal and malignant breast tissue in controls and tamoxifen treated patients.
  • Vis forfatter(e) (2010). Effects of CYP2C19 genotype on tamoxifen and estrogen metabolism.
  • Vis forfatter(e) (2010). Distribution of tamoxifen and five metabolites into normal and malignant human breast cancer tissue during conventional and low dose treatment.
  • Vis forfatter(e) (2009). Relations between FSH, SHBG and tamoxifen metabolism during steady state tamoxifen treatment.
  • Vis forfatter(e) (2007). Effect of CYP2D6 and SULT1A1 Genotypes on the serum concentration of 4-OHtamoxifen and 4-OH-N-Demethyltamoxifen during steady state treatment of breast cancer patients.
  • Vis forfatter(e) (2007). A study of association between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferae 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady sate tamoxifen treatment.
  • Vis forfatter(e) (2005). Relationship between CYP2D6 and SULT1A1 genotypes and serum concentrations of tamoxifen and its metabolites during steady state treatment in breast cancer patients.
  • Vis forfatter(e) (2005). Relationship between CYP2D6 and SULT1A1 genotype and serum concentration of tamoxifen and its metabolites during steady state treatment in breast cancer patients.
  • Vis forfatter(e) (2005). Effects of low-dose tamoxifen treatment on expression of drug-metabolising enzymes in rat liver in relation to administration route.
  • Vis forfatter(e) (2004). Tamoxifen metabolism and induction of hepatic drug-metabolizing enzymes in nude rats.
  • Vis forfatter(e) (2004). Quantification of serum tamoxifen and metabolites by liquid chromatography-tandem mass spectrometry.
  • Vis forfatter(e) (2002). Tamoxifen metabolism in immunocompromised rats and mice.

Se fullstendig oversikt over publikasjoner i CRIStin.